Tanzania recalls drugs for Chinese blood pressure because of cancer risk – News

Dar es Salaam The Food and Drugs Authority of Tanzania (TFDA) recalls from the market of Chinese-made drugs that were used to treat high blood pressure and heart failure after tests laboratory tests in the United States revealed that the drugs contain carcinogens (carcinogens). 19659002] The spokesperson of the TFDA, Mrs. Gaudensia Semwaza, declared The Citizen that the drugs, Dynaval Co 80 / 12.5 mg, 160 / 12.5 mg and 160/25 mg, are already recalled since last Friday. This measure, she says, was a precautionary measure

The Citizen confirmed that the drugs were still on the market until Wednesday, July 25 as regulators strive to solve the problem. require the authorities to take such action within 14 days of the drug safety alert. Ms Semwaza said the recall process would continue for 14 days

Similar steps were taken across Europe after the European Medicines Agency (EMA) raised the potential risk of drug cancer on July 5th. This year, the US Food and Drug Administration (FDA) has advised health care professionals and patients to voluntarily recall several drugs containing the active ingredient, valsartan, used to treat high blood pressure. and heart failure

. due to an impurity, N-nitrosodimethylamine (NDMA), which has been found in the recalled products, said the FDA in a statement.

"However, not all products containing valsartan are listed NDMA is clbadified as a probable carcinogen to humans (a substance which can cause cancer) according to the results of the tests in the laboratory. "The FDA warned that the presence of NDMA was unexpected and that it would be linked to changes in the way FDA added.

The FDA review is underway and included the study of NDMA levels in the recalled products, badessing the possible effect on the patients who took them and the measures that can be taken to reduce or eliminate the impurity of future batches produced by the company.

South African media reports show that the company that manufactured the drug Zhejiang Huahai has already acknowledged that there was an impurity in some of his valsartan, who said he had sales of 50 million dollars s in 2017 and added on Monday this week that countries were recalling products as a precautionary measure.